Head to head

CJC-1295 without DAC vs Hexarelin

GH secretagogue

Two compounds that are more often stacked than compared — the side-by-side data, and what actually separates them.

Verdict

Usually stacked — and only Hexarelin has human trial data

CJC-1295 without DAC and Hexarelin appear in each other's stacks in this dataset, so the most common real-world use is together rather than instead of. If you are picking one, the evidence is the honest tiebreak: Hexarelin has controlled human trials behind it, without an approval, while CJC-1295 without DAC has no controlled human data at all, so the numbers here come from practice, not a label. That is a difference in how much is known, not a verdict on how well either works.

What you are actually choosing between

Before anything else: the dataset lists CJC-1295 without DAC and Hexarelin in each other's stacks. They are run together more often than they are chosen between, so if you came here for a winner, the first honest answer is that this may not be an either/or.

Both are classed here as growth hormone secretagogues, so this is a within-class choice: the mechanism is broadly shared and what separates them is kinetics, route, and how much has actually been tested.

The overlap is muscle growth, recovery and sleep, and injury repair. On this site's goal weighting — an editorial priority score, not a measure of effect size — CJC-1295 without DAC rates 3/5 for muscle growth and Hexarelin rates 4/5.

The evidence

This is the part that decides most of it. Hexarelin has controlled human trials behind it, without an approval — human GH-response data is real, but the response blunts within weeks. CJC-1295 without DAC has no controlled human data at all, so the numbers here come from practice, not a label — the closest approved comparators are sermorelin and tesamorelin. That gap is the headline, and it is a statement about the literature rather than a promise about you: a compound with trial data can still do nothing for your case, and one without it is unproven rather than disproven.

How they differ in practice

CJC-1295 without DAC is a subcutaneous injection; Hexarelin is a subcutaneous injection and an intramuscular injection. Both are injected, so route does not decide this one.

Half-lives are close — 30 min for CJC-1295 without DAC, 1 h for Hexarelin — and both are dosed once daily, so the rhythm of actually running them is the same.

Committed time differs: CJC-1295 without DAC runs 12 weeks, Hexarelin runs 4 weeks.

Risk and difficulty

CJC-1295 without DAC is rated intermediate here and Hexarelin advanced. That rating is about how much can go wrong in handling, dosing and monitoring, not about how well either works.

Source notes

What the evidence actually says

Verbatim, so you can check the verdict above against what it was built from.

CJC-1295 without DAC (Mod GRF 1-29)

Tetra-substituted GHRH (1-29) with no Drug Affinity Complex, so it clears in roughly 30 minutes and produces a single discrete GH pulse. That short half-life is the whole point: it is dosed once to three times daily, typically around 100 mcg (roughly 1-2 mcg/kg, a saturating pulse dose) on an empty stomach, and is paired with a ghrelin agonist such as ipamorelin. It is NOT an approved medicine; the closest approved comparators are sermorelin and tesamorelin. Consumer supply is research-chemical grade and dosing convention comes from practice, not from a label.

Hexarelin

Synthetic hexapeptide ghrelin receptor (GHS-R1a) agonist and one of the most potent GH secretagogues studied in humans, with additional cardiac data. Its defining practical problem is tachyphylaxis: repeated dosing blunts the GH response over roughly two to four weeks, which is why it is cycled short rather than run continuously. It also lacks the selectivity of ipamorelin, so prolactin and cortisol elevation are expected at higher doses.

Side by side

The numbers

CJC-1295 without DAC compared with Hexarelin
Attribute	CJC-1295 without DAC	Hexarelin
Class	GH secretagogue	GH secretagogue
Routes	Subcutaneous	Subcutaneous, Intramuscular
Dose range	100 mcg–300 mcg (typical 100 mcg)	50 mcg–200 mcg (typical 100 mcg)
Frequency	Once daily	Once daily
Half-life	30 min	1 h
Cycle length	12 weeks	4 weeks
Experience	Intermediate	Advanced
Evidence	Practice-derived only	Controlled human trials
Contraindications	Pregnant / nursing Active malignancy Under 18	Pregnant / nursing Active malignancy Under 18
Side effects	Injection site redness, itching or a short-lived welt Head rush, flushing or warmth in the minutes after injection Mild water retention Tingling or numbness in the hands Drowsiness when dosed pre-bed	Marked receptor desensitisation — the GH response falls off within a few weeks of continuous daily use, so cycles are kept short with washout periods Raises prolactin and cortisol more than ipamorelin does Strong hunger spike within 20 to 30 minutes of dosing Water retention, puffiness and numb or tingling hands Head rush, flushing or transient light-headedness after injection Injection site irritation

Turn a typical dose into a mark on the syringe: CJC-1295 without DACHexarelin

Goals

Where they overlap, and where they do not

Goal	CJC-1295 without DAC	Hexarelin
muscle growth	CJC-1295 without DAC: 3/5	Hexarelin: 4/5
recovery and sleep	CJC-1295 without DAC: 4/5	Hexarelin: 3/5
injury repair	CJC-1295 without DAC: 3/5	Hexarelin: 3/5
fat loss	CJC-1295 without DAC: 2/5	Hexarelin: 2/5
longevity	CJC-1295 without DAC: 2/5	Hexarelin: 1/5

They overlap on 5 goals and diverge on 0. Weights are this site’s editorial priority score out of 5 — how central a goal is to why people use a compound. They are not effect sizes and two 5s do not mean two equal results.

Go deeper

MonographCJC-1295 without DAC (Mod GRF 1-29)Mechanism, protocol, storage, sources.MonographHexarelinMechanism, protocol, storage, sources.ToolReconstitution calculatorTurn either dose above into a mark on the syringe.

Other comparisons with these two

Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.